[12] Patent
[11] Patent No.:GC0010747  
[45] Date of Publishing the Grant of the Patent: 31/Oct /2019                63/2019  
Number of the Decision to Grant the Patent:2019/156865
Date of the Decision to Grant the Patent:10/Sep/2019

[21] Application No.:GC 2012-20641

[22] Filing Date:29/2/2012

[30] Priority:

[33] State [32] Priority date [31] Priority No.
EP
2/3/2011
11156665.9

[72] Inventors:1- Thomas U. Hofer،2- Ralf Hosse،3- Ekkehard Moessner،4- Pablo Umana

[73] Owner: Roche Glycart AG, Wagistrasse 18, CH-8952, Schlieren, Switzerland

[74] Agent: Kadasa Law Firm

  

 

  

[51]IPC:
Int. Cl.: A61K 39/395; A61P 35/00; C07K 16/30 (2006.01)

[56] Cited Documents:

-ASHRAF S Q ET AL: Humanised lgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis,BRITISH JOURNAL OF CANCER. 17 November 2009
-CONAGHAN P J ET AL: Targeted killing of colorectal cancer cell lines by a humanised lgG1 monoclonal antibody that binds to membrane- bound carcinoembryonic antigen, BRITISH JOURNAL OF CANCER. 8 April 2008
-STEWART L M ET AL: Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell- bound carcinoembryonic antigen, CANCER IMMUNOLOGYAND IMUNOTHERAPY. 1 January 1999
-GARAMBOIS VERONIQUE ET AL: Fully human lgG and lgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designedfor radioimmunotherapy (RIT) of colorectal cancers. 15 October 2004
--WO 9506067 A1 (IMP CANCER RES TECH [GB]; BODMER WALTER FRED [GB]; DURBIN HELGA [GB];) 2 March 1995
 
Examiner: PH. Nada M. AlBehaiji

[54] CEA ANTIBODIES
[57] Abstract: The present invention provides antigen binding molecules (ABMs) which bind membrane-bound CEA, including ABMs with improved therapeutic properties, and methods of using the same.
No. of claims: 27     No. of figures: 38


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.